|
|
楼主 |
发表于 2024-5-9 10:18:51
|
显示全部楼层
, n' V& z' s5 ]6 Y" j. O
我看了下，入选今年ASCO的中肿研究，有4项是随机、3期临床试验，2项鼻咽癌+2项肺癌，这4项应该都能发很不错的文章，其余1-2期的应该也有子刊的水平5 @. t$ P+ H( d! \, ]2 `, E1 {
9 R5 o9 C, m7 C9 S( X8 jIvonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial.. N5 b4 t5 p0 L: W
Ivonescimab联合化疗治疗接受EGFR-TKI治疗进展的EGFR突变非鳞状NSCLC患者(HARMONi-A)：一项随机、双盲、多中心、III期试验
: M' @" _1 ]0 A' M( y: H* J5 m讲者：张力 中山大学肿瘤防治中心
9 I+ A# b4 z$ ^# q" u
. i G" m9 n# M0 hAdjuvant icotinib of 12 months or 6 months versus observation following adjuvant chemotherapy for resected EGFR-mutated stage II–IIIA non-small-cell lung cancer (ICTAN, GASTO1002): A randomized phase 3 trial.2 m0 m# {; t$ Y- D
可切除EGFR突变II-IIIA期NSCLC接受12个月或6个月的埃克替尼辅助治疗对比辅助化疗后观察：一项随机III期试验(ICTAN，GASTO1002)
/ ~$ e. w5 l! a8 J( d+ |% N讲者：王思愚 中山大学肿瘤防治中心
% Z6 c+ M* I# K3 Z9 c, r& [2 s" Z+ t- g- u
Tislelizumab versus placebo combined with induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant tislelizumab or placebo for locoregionally advanced nasopharyngeal carcinoma: Interim analysis of a multicenter, randomized, placebo-controlled, double-blind, phase 3 trial.
4 A2 [+ F$ U, [/ P替雷利珠单抗对比安慰剂联合诱导化疗序贯同步放化疗，继以替雷利珠单抗或安慰剂辅助治疗局部晚期鼻咽癌：一项多中心、随机、安慰剂对照、双盲、III期试验的期中分析/ b0 Z: k9 _6 m$ [2 s
讲者：陈秋燕 中山大学肿瘤防治中心# P0 ]9 j! t4 _3 N0 s7 ]
0 M, h+ T" E) E" g% FAdjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial.
3 A4 ]/ x6 `5 o `) v. n卡瑞利珠单抗辅助治疗高危局部晚期鼻咽癌(DIPPER)：一项多中心、开放标签、III期随机对照试验
8 l$ |3 S/ W% X8 q" t; E( P8 z2 ^+ ^讲者：刘需 中山大学肿瘤防治中心
' w9 o. `& {5 z: f, v0 {9 j0 J: ^( }/ F
|
|
[复制链接]
发表于 2024-5-9 08:59:18
